Impact of glucagon-like peptide 1 agonist deprescription in type 2 diabetes in a real-world setting: a propensity score matched cohort study
As Koniver suggests, healthcare providers may need to explore creative alternatives to ensure patients can access these beneficial treatments without facing extreme financial burden
Because they are nutrients and not drugs, no prescription is needed, and there are no negative side effects
Genetic variation in your GLP1R gene and metabolic pathways determines how sensitively you respond to the medication, affecting nausea severity and appetite suppression timing
For example, the LEADER trial showed that liraglutide reduced MACEs risk by 13%, while the SUSTAIN-6 trial indicated a 26% reduction with semaglutide
Using functional genomics data (ATAC-seq, ChIP-seq, and RNA-seq) (40)